Is There a Mounjaro Biosimilar Available in the UK?

Step 1, Understand what a biosimilar is and why none exist yet for tirzepatide

Biosimilars are medicines developed to be highly similar to a biological reference product once that product's patent protection lapses. They go through a regulatory approval process in their own right, they are not simple copies. For small-molecule drugs, the equivalent is a generic; for the larger, more complex molecules used in modern weight-loss treatments, the term is biosimilar.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, the only medicine of its kind licensed for weight management in the UK, described in detail on our Mounjaro page. Because Eli Lilly's patents on tirzepatide remain active, no manufacturer can submit a biosimilar for UK regulatory review yet. The MHRA licenses medicines for the UK market; the EMA covers the EU. Neither has received or approved a tirzepatide biosimilar application as of summer 2026. That is simply where the patent timeline sits.

This matters for anyone searching the term hoping to find a cheaper route to treatment. There is no legitimate cheaper-by-design version on the market. Any listing claiming otherwise is not a UK-licensed product.

Step 2, Recognise what's being sold as a "biosimilar" or "generic" Mounjaro online

The MHRA has been explicit: unlicensed sellers, many operating through social media, have been offering products described loosely as generic tirzepatide, compounded tirzepatide, or cheap Mounjaro alternatives. These are not biosimilars in any regulatory sense. A genuine biosimilar requires full MHRA approval, a licensed supply chain, and dispensing through a pharmacy you can verify on the GPhC register.

In October 2025 enforcement teams raided the first illicit UK site manufacturing counterfeit tirzepatide pens, seizing around 20 million doses of illegally traded weight-loss medicines worth approximately £45 million. Some fake pens seized in earlier operations contained insulin rather than the labelled medicine, a risk serious enough that the MHRA's Yellow Card reporting service invites members of the public to flag suspect sellers directly.

The practical test: if something is priced far below the private market, sold without a clinical consultation, or described as a generic form of a medicine still under patent, it is a red flag. The full background on tirzepatide explains the licensed product's supply chain in plain terms.

Step 3, What to expect when biosimilars eventually arrive

Patent expiry does not flip a switch. When tirzepatide biosimilars do become eligible for regulatory submission (likely toward the end of this decade) they will still need to demonstrate high similarity to the reference product, go through the MHRA approval process, and be prescribed following a clinical assessment. Prescription-only status does not change just because a medicine becomes cheaper to manufacture.

Competition from biosimilars historically does reduce prices over time; that happened with adalimumab (the active ingredient in Humira) and is expected with semaglutide once its patents expire too. For patients considering alternatives to Mounjaro in the meantime, the landscape is genuinely different from what search results sometimes suggest. Licensed options in the UK for weight management currently include Mounjaro and Wegovy (semaglutide) (both injectable) and the newly approved Wegovy tablet, oral semaglutide. None of these are biosimilars of each other; they are separately licensed originator products.

The cost context for private Mounjaro is set by Eli Lilly's UK pricing, which changed in September 2025. Typical private prices since then range roughly £149 to £375 per month depending on dose and provider, as widely reported. For a fuller picture of what affects price and what a legitimate private prescription includes, our weight-loss treatment overview covers the honest breakdown.

Step 4, The route to licensed tirzepatide right now

For anyone in the UK today, the only path to genuine Mounjaro is a prescription from a registered prescriber following a clinical assessment of your full medical picture. That applies whether you go through a GP, a specialist weight management service, or a regulated online pharmacy. A question our prescribers hear regularly: does holding a current prescription elsewhere speed things up? For patients transferring from another provider, the short answer is yes, existing evidence of treatment is part of the clinical review.

If you are already on Mounjaro and wondering about products comparable to tirzepatide should your supply be disrupted, that is worth raising with your prescriber directly rather than sourcing something unlicensed. Supply from the licensed UK chain has stabilised considerably since the shortage period of 2023 and 2024. The right conversation to have, if you have questions about your specific situation, is with a clinician who has your full history, and patients with particular mental health conditions, including those researching Mounjaro and bipolar disorder, will find that our clinical team can address those specific concerns directly. Our clinical team is available seven days a week for aftercare queries.